Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampalamo Talamo, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Frits van Rhee, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 929.

https://doi.org/10.1182/blood.V104.11.929.929

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Michele Cottler-Fox, MD, David Holley, BA, Linda Whigham, HNC, Julie Stover, BA, Erik Rasmussen, MS, Maurizio Zangari, MD, Guido Tricot, MD, PhD, Barthel Barlogie, MD, PhD

Blood (2004) 104 (11): 2884.

https://doi.org/10.1182/blood.V104.11.2884.2884

Published: 2004

Journal Articles

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Maurizio Zangari, MD, Julie Stover, Lisa Jackson, Teresa Milner, Athanasios Fassas, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 538.

https://doi.org/10.1182/blood.V104.11.538.538

Published: 2004

NARROW

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Email alerts

ASH Publications

American Society of Hematology

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only